From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

Por DeFronzo, Ralph A.
Publicado em 2009

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes

Por DeFronzo, Ralph A.
Publicado em 2011

The EMPA-REG study: What has it told us?: A diabetologist’s perspective

Por DeFronzo, Ralph A.
Publicado no J Diabetes Complications (2015)

COMBINATION THERAPY WITH GLP-1 RECEPTOR AGONIST AND SGLT2 INHIBITOR

Por DeFronzo, Ralph A.
Publicado no Diabetes Obes Metab (2017)

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type

Por Miyazaki, Yoshinori, DeFronzo, Ralph A
Publicado em 2009

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes

Por DeFronzo, Ralph A., Tripathy, Devjit
Publicado em 2009

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!

Por Schwartz, Stanley, DeFronzo, Ralph A.
Publicado em 2013

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention

Por DeFronzo, Ralph A., Abdul-Ghani, Muhammad
Publicado em 2011

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm

Por Abdul-Ghani, Muhammad, DeFronzo, Ralph A.
Publicado no Diabetes Care (2017)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes

Por Abdul-Ghani, Muhammad A., DeFronzo, Ralph A.
Publicado em 2009

Pathogenesis of Insulin Resistance in Skeletal Muscle

Por Abdul-Ghani, Muhammad A., DeFronzo, Ralph A.
Publicado em 2010

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Por Triplitt, Curtis, Cersosimo, Eugenio, DeFronzo, Ralph A
Publicado em 2010

Beta Cell Formation in vivo Through Cellular Networking, Integration and Processing (CNIP) in Wild Type Adult Mice

Por Doiron, Bruno, Hu, Wenchao, DeFronzo, Ralph A.
Publicado no Curr Pharm Biotechnol (2016)

Dapagliflozin for the treatment of type 2 diabetes

Por Abdul-Ghani, Muhammad A, DeFronzo, Ralph A
Publicado no Expert Opin Pharmacother (2013)

Lowering Plasma Glucose Concentration by Inhibiting Renal Sodium-Glucose Co-Transport

Por Abdul-Ghani, Muhammad A, DeFronzo, Ralph A
Publicado no J Intern Med (2014)

Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

Por DeFronzo, Ralph A., Eldor, Roy, Abdul-Ghani, Muhammad
Publicado em 2013

In Vivo Actions of Peroxisome Proliferator–Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion

Por Eldor, Roy, DeFronzo, Ralph A., Abdul-Ghani, Muhammad
Publicado em 2013

Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?

Por Liu, Jiwen (Jim), Lee, TaeWeon, DeFronzo, Ralph A.
Publicado em 2012

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans

Por Abdul-Ghani, Muhammad A., DeFronzo, Ralph A., Norton, Luke
Publicado em 2013

Treatment of prediabetes

Por Kanat, Mustafa, DeFronzo, Ralph A, Abdul-Ghani, Muhammad A
Publicado no World J Diabetes (2015)